What is VIRTUE Diagnostics?
Founded in 2019 and headquartered in Shanghai, VIRTUE Diagnostics operates as a specialized IVD enterprise dedicated to addressing critical gaps in infectious disease, oncology, and chronic disease management. The company distinguishes itself through a multi-platform technological approach that spans the entire patient care continuum. From early-stage screening and initial diagnostic protocols to complex treatment monitoring and minimal residual disease (MRD) management, VIRTUE Diagnostics provides comprehensive clinical solutions. Its market position is defined by a commitment to high-precision diagnostics, aiming to improve patient outcomes through integrated, data-driven medical insights that cater to both domestic and international healthcare demands.
How much funding has VIRTUE Diagnostics raised?
VIRTUE Diagnostics has raised a total of $130M across 2 funding rounds:
Series A
$30M
Series B
$100M
Series A (2020): $30M with participation from Lily Asia Ventures
Series B (2022): $100M, investors not publicly disclosed
Key Investors in VIRTUE Diagnostics
Lily Asia Ventures
A prominent venture capital firm focused on identifying and scaling high-growth companies within the healthcare and life sciences sectors in Asia.
Undisclosed Investor
An institutional partner providing strategic capital to support the long-term development and market expansion of innovative diagnostic technologies.
Undisclosed Investor
A professional investment entity participating in the latest funding round to bolster the company's clinical diagnostic infrastructure.
What's next for VIRTUE Diagnostics?
With the successful closure of its latest financing round, VIRTUE Diagnostics is well-positioned to accelerate its R&D initiatives and expand its commercial reach. The strategic allocation of this capital will likely focus on deepening the company's diagnostic portfolio and enhancing its proprietary technology platforms to maintain a competitive edge in the rapidly evolving IVD market. As the firm transitions into a more mature operational phase, stakeholders will be monitoring its ability to scale production, navigate regulatory landscapes, and integrate its diagnostic solutions into broader clinical workflows. The focus remains on achieving sustainable growth while maintaining the high-quality standards required for advanced disease management and patient-centric care.
See full VIRTUE Diagnostics company page
